
Opinion|Videos|June 6, 2024
Key Findings and Conclusions from MARIPOSA-2 Trial
The panelist summarizes the major findings from MARIPOSA-2 and their conclusions about amivantamab regimens improving outcomes in osimertinib-resistant NSCLC.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5





















































































